Flowchart depicting the random selection of health care facilities and patients included in the study.

<p>Flowchart depicting the random selection of health care facilities and patients included in the study.</p

Patients’ socio-demographic, clinical, and treatment characteristics (n = 836).

<p>* values are n (%) unless otherwise indicated.</p><p>^a at enrolment in HIV care.</p><p>^b at start cART.</p><p>^c at study entry or at last known clinic/pharmacy refill visit date.</p><p>^d according to the revised World Health Organization clinical staging of HIV/AIDS for adults and adolescents, 2005 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0130649#pone.0130649.ref051" target="_blank">51</a>].</p><p>TDF, Tenofovir; AZT, Zidovudine; d4T, Stavudine.</p><p>SD, standard deviation; IQR, inter-quartile range.</p><p>Patients’ socio-demographic, clinical, and treatment characteristics (n = 836).</p

Results of the Cox regression model showing predictors of attrition from HIV care among HIV infected adults on cART.

<p>^a at enrolment in HIV care.</p><p>^b at start cART.</p><p>^c according to the revised World Health Organization clinical staging of HIV/AIDS for adults and adolescents, 2005 [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0130649#pone.0130649.ref051" target="_blank">51</a>].</p><p>d4T, Stavudine; AZT, Zidovudine; TDF, Tenofovir.</p><p>HR, hazard ratio.</p><p>* p-value < 0.2.</p><p>^‡ p-value < 0.05.</p><p>1 = reference category.</p><p>Results of the Cox regression model showing predictors of attrition from HIV care among HIV infected adults on cART.</p

Prostate cancer (PC) knowledge by participation to risk-based PC screening, three months before invitation to screening.

<p>Prostate cancer (PC) knowledge by participation to risk-based PC screening, three months before invitation to screening.</p

Men’s worry and perceived vulnerability to prostate cancer (PC) by participation to risk-based PC screening, three months before invitation to screening.

<p>Men’s worry and perceived vulnerability to prostate cancer (PC) by participation to risk-based PC screening, three months before invitation to screening.</p

Health behaviour scale scores by participation to risk-based PC screening, three months before invitation to screening.

<p>Health behaviour scale scores by participation to risk-based PC screening, three months before invitation to screening.</p

Data for goal disturbance, cortisol levels, CAR, DCS, and COMT over time (n = 72).

<p>Paired samples t-tests were used to test significant differences between time 2 and time 3, and ANOVA’s with COMT genotype as between-group factor to test significant differences in cortisol levels between genotypes.</p

Hierarchical regression analyses predicting cortisol 7 months post-diagnosis (Time 2).

<p>*<i>p</i> < 0.05</p><p>**<i>p</i> < 0.01</p><p>Hierarchical regression analyses predicting cortisol 7 months post-diagnosis (Time 2).</p

Hierarchical regression analyses predicting cortisol 18 months post-diagnosis (Time 3).

<p>*<i>p</i> < 0.05</p><p>**<i>p</i> < 0.01</p><p>Hierarchical regression analyses predicting cortisol 18 months post-diagnosis (Time 3).</p

Patients’ demographics.

<p>(n = 72) (percentages may not add up to 100% due to missing data).</p><p>Patients’ demographics.</p